Vernagen aims for the discovery and development of mRNA based therapeutic biologics. Vernagen utilizes extensive basic science knowledge to design innovative mRNA platforms that will optimally produce target proteins in cells. mRNA biologics targeting immunological and genetic disorders and vaccines against infectious diseases are our current pipeline concepts. Therapeutic platforms developed by Vernagen will be validated in pre-clinical/animal models for their efficacy and safety and ultimately in human trials.